



**About us**


Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,815 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 325,188 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company provides related medical services in the field of Care Coordination.

**Key figures – 1st half of 2018**

		Q2 2018	Growth cc	H1 2018	Growth cc
Revenue	€	4,214 M	2%	8,189 M	0%
Operating income (EBIT)	€	1,401 M	162%	1,898 M	68%
Net income <sup>1</sup>	€	994 M	303%	1,273 M	141%
Basic earnings per share	€	3.24	303%	4.15	141%
Net cash provided by (used in) operating activities	€	656 M		611 M	
Free cash flow	€	429 M		165 M	
Free cash flow after investing activities	€	1,927 M		1,482 M	
Employees				111,263	

<sup>1</sup> attributable to shareholders of Fresenius Medical Care AG & Co. KGaA


**Q2 2018: Revenue per region (in € million)**




**H1 2018: Patients, treatments, clinics**

	Patients	Treatments (in M)	Clinics
North America	199,527	15.1	2,439
EMEA	63,589	4.8	758
Asia-Pacific	30,578	2.1	385
Latin America	31,494	2.5	233
<b>Total</b>	<b>325,188</b>	<b>24.6</b>	<b>3,815</b>

**Basic earnings & dividend per share**



**Balance sheet (in € billion)**



**Strategy**

*Our strategic plan is built around four core competencies that will support us in the years to come:*

- Innovating products
- Operating outpatient facilities
- Standardizing medical procedures
- Coordinating patients efficiently

**Goals for 2018**

Revenue growth on a comparable basis	5 to 7%
Net income growth on a comparable basis	13 to 15%
Net income growth adjusted	7 to 9%



**History**

- September 30, 1996: Foundation of the company
- October 1, 1996: First listing of the shares on the Frankfurt Stock Exchange
- October 2, 1996: First listing of the shares on the New York Stock Exchange
- As of September 20, 1999: Inclusion in the DAX (Deutscher Aktienindex)

**Share price - last 12 months (in €)**



**Basic share data**


**Ticker Symbols:**

Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / ADR NYSE:	FMEG.DE/FMS.N
Bloomberg: XETRA / ADR NYSE:	FME GY / FMS US

**Security Identification numbers:**

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

**Geographical distribution of identified shares**



**Share capital (as of end of July 2018)**

Number of shares outstanding	308,215,905
<i>Fresenius SE &amp; Co. KGaA</i>	30.6%
Free float	~69%
Market capitalization	~26 BN €

**Ratings**

Standard & Poor's	BBB- / positive outlook
Moody's	Baa3 / stable outlook
Fitch	BBB- / stable outlook

**Management Board**

- Rice Powell (Chairman)
- Michael Brosnan (Finance)
- Bill Valle (North America)
- Dr. Olaf Schermeier (Research & Development)
- Kent Wanzek (Production & Quality)
- Harry de Wit (Asia-Pacific)

**Supervisory Board**

- Dr. Dieter Schenk (Chairman)
- Rolf A. Classon
- William P. Johnston
- Deborah Doyle McWhinney
- Pascale Witz

**Financial calendar**

Report on the 3rd quarter 2018: October 30, 2018

Please note that these dates might be subject to changes.

**Contacts**

Fresenius Medical Care AG & Co. KGaA  
Investor Relations & Corporate Communications  
Else-Kröner-Str. 1, 61352 Bad Homburg  
Email: [ir@fmc-ag.com](mailto:ir@fmc-ag.com)

**Dr. Dominik Heger**

SVP & Head of IR & Corp. Communications  
P: +49(0)6172-609-2525 F: +49(0)6172-609-2301